References
- BresslerNMAge-related macular degeneration is the leading cause of blindnessJAMA20042911900190115108691
- LimLSMitchellPSeddonJMHolzFGWongTYAge-related macular degenerationLancet20123791728173822559899
- BrownDMKaiserPKMichelsMRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med20063551432144417021319
- Schmidt-ErfurthUKaiserPKKorobelnikJFIntravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of VIEW studiesOphthalmology201412119320124084500
- RofaghaSBhisitkulRBBoyerDSSaddaSRZhangKSEVEN-UP Study GroupSeven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)Ophthalmology20131202292229923642856
- RosenfeldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med20063551419143117021318
- StewartMWAflibercept (VEGF Trap-eye): the newest anti-VEGF drugBr J Ophthalmol2012961157115822446028
- MarukoIIidaTSaitoMNagayamaDSaitoKClinical characteristics of exudative age-related macular degeneration in Japanese patientsAm J Ophthalmol2007144152217509509
- OginoTTakedaMImaizumiHOkushibaUPhotodynamic therapy for age-related macular degeneration in Japanese patients: results after one yearJpn J Ophthalmol20075121021517554484
- OishiATsujikawaAYamashiroKOne-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcomeAm J Ophthalmol201515985386025634529
- KawamuraAYuzawaMMoriRHaruyamaMYuzawaTKIndocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two typesActa Ophthalmol201391e474e48123848133
- TanCSNgoWKLimLWLimTHA novel classification of the vascular patterns of polypoidal choloidal vasculopathy and its relation to clinical outcomesBr J Ophthalmol2014981528153324997181
- CoscasGLupidiMCoscasFToward a specific classificatio of polypoidal choroidal vasculopathy: idiopathic disease or subtype of age-related macular degenerationInvest Ophthalmol Vis Sci2015563187319526024102
- HondaSMikiAYanagisawaSMatsumiyaWNagaiTTsukaharaYComparison of the outcomes of photodynamic therapy between two angiographic subtypes of polypoidal choroidal vasculopathyOphthalmologica2014232929624993059
- JeongSSagongMShort-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathyBr J Ophthalmol201710175876327597740
- Axer-SiegelRBorEBourlaDHWeinbergerDMimouniKIntravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuityRetina2012321811182022825407
- KatoAYasukawaTSugaKIntravitreal ranibizumab for patients with neovascular age-related macular degeneration with good baseline visual acuityOphthalmologica2015233273425412682
- LeeAYLeeCSButtTUK AMD EMR USERS group report V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12Br J Ophthalmol2015991045105025680619
- TakahashiKOguraYIshibashiTShiragaFYuzawaMTreatment guidelines for age-related macular degenerationNippon Ganka Gakkai Zasshi20121161150115523379205
- ArcinueCAMaFBarteselliGSharpstenLGomezMLFreemanWROne-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degenerationAm J Ophthalmol201515942643625461263
- ChangAALiHBroadheadGKIntravitreal aflibercept for treatment-resistant neovascular age-related macular degenerationOphthalmology201412118819224144450
- KuehleweinLBansalMLenisTLOptical coherence tomography angiography of type 1 neovascularization in age-related macular degenerationAm J Ophthalmol201516073974826164826
- NomuraYYanagiYIntravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeabilityJpn J Ophthalmol20155961265
- YamamotoAOkadaAAKanoMOne-year results of intravitreal aflibercept for polypoidal choroidal vasculopathyOphthalmology20151221866187226088619